Practical experience of ustekinumab in the treatment of psoriasis: Experience from a multicentre, retrospective case cohort study across the U.K. and Ireland

British Journal of Dermatology

Volumn 166, Issue 1, 2012, Pages 189-195

  Laws, P M ^a   Downs, A M ^b   Parslew, R ^c   Dever, B ^c   Smith, C H ^d   Barker, J N ^d   Moriarty, B ^d   Murphy, R ^e   Kirby, B ^f,g   Burden, A D ^h   McBride, S ⁱ   Anstey, A V ^j   O'Shea, S ^f   Ralph, N ^g   Buckley, C ^g   Griffiths, C E M ^a   Warren, R B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^c ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^g WATERFORD REGIONAL HOSPITAL   (Ireland)

^h WESTERN INFIRMARY   (United Kingdom)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

^j ROYAL GWENT HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; ETRETIN; METHOTREXATE; USTEKINUMAB;

ADULT; AGED; ARTICLE; BLADDER CANCER; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; IRELAND; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON SMALL CELL BLADDER CANCER; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SCALP INFECTION; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; TUBERCULOSIS; UNITED KINGDOM; WEIGHT GAIN;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL AGENTS; BODY MASS INDEX; COST OF ILLNESS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84555202364     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10638.x     Document Type: Article

References (13)

1. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74. (Pubitemid 351671883)
2. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84. (Pubitemid 351671884)
3. Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
4. Ghislain PD, Poulin Y, Wasel N, et al. Maintenance of long-term efficacy of ustekinumab through year 3 for patients with moderate-to-severe psoriasis. 19th Congress of the European Academy of Dermatology and Venereology, Gothenberg, Sweden, 2010; P589.
5. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-46.
6. Warren RB, Brown BC, Lavery D, et al. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2010; 163: 859-62.
7. Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2009; 160: 162-9.
8. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
9. National Institute for Health and Clinical Excellence. Ustekinumab for the Treatment of Adults with Moderate to Severe Psoriasis, 2009. Available at: (last accessed 13 October 2011).
10. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-40.
11. Laws P, Barton A, Warren RB,. Psoriatic arthritis-what the dermatologist needs to know. J Eur Acad Dermatol Venereol 2010; 24: 1270-7.
12. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009; 49: 162-75.
13. Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010; 63: 571-9.